Citations

Mayo Clinic

Showing 10 of 108572 citations.

Abstract 18878: Right Heart Valves Affected by Cancer-Related Non-Bacterial Thrombotic Endocarditis as Potential Cause of Pulmonary Embolism
Alladi, Sai Swetha, Klarich, Kyle W. , Kurmann, Reto , Hodge, David O. , Dariusz, Patrzalek, Wysokinska, Ewa , Houghton, Damon E. , Wysokiński, Waldemar E.

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18878 Get It

Background: Ca-NBTE primarily affects the mitral valve (MV) and aortic valve (AV), with rare involvement of the right heart valves. Premortem descriptions of this condition are limited to a few case reports. This study presents an initial clinical series focusing on patients with Ca-NBTE specifically affecting their right heart valves. We describe the underlying cancers, types of valve lesions, and associated embolic complications. Patients and Methods: A electronic search of medical records (March 31, 2002, to June 30, 2022) was followed by a manual review to identify adult patients with echocardiographically detected NBTE, active cancer, and no infectious endocarditis or lupus anticoagulant/antiphospholipid antibodies. Results: Out of 115 identified patients with Ca-NBTE (mean age 63.2±9.7 years, 66.1% female), there were 8 cases (7.0%) affecting right heart valves (mean age 64.5±12.1 years, 3 females) with underlying cancer: pancreatic (n=3), lung (n= 2), genitourinary (n=1), gastric (n=1) and neck sarcomatoid carcinoma (n=1). TV was affected in 8 patients and PV in one case; 4 patients had Ca-NBTE limited only to PV, 2 patients had MV and TV, 1 patient had mitral, aortic and TV, and 1 patient with pancreatic cancer had all four valves affected by NBTE. 5 patients had embolic complications to the brain with one patient in that group also experiencing emboli to the kidney and spleen. Out of 4 patients with NBTE limited to TV, two still had brain emboli, one had only pulmonary embolism, and one patient had no embolic complications. Conclusion: Around 7% of Ca-NBTE cases involve the right heart valves, with half of these cases limited to the TV. The cancer profile in these cases resembles that seen in left heart valve involvement.
Abstract 18819: Detection of Systolic Dysfunction in Pediatric Patients Using an Artificial Intelligence-Enabled Electrocardiogram
Anjewierden, Scott , O’Sullivan, Donnchadh , Greason, Grace , Friedman, Paul A. , Anderson, Jason, Kashou, Anthony H. , Eidem, Benjamin W., Johnson, Jonathan N. , Madhavan, Malini , Attia, Zachi I. , López-Jiménez, Francisco , Noseworthy, Peter A. , Anderson, Jason, Niaz, Talha

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18819 Get It

Introduction: Left and right ventricular systolic dysfunction (LVSD and RVSD respectively) contribute to considerable pediatric morbidity. Both LVSD and RVSD can occur in children before symptom onset, emphasizing the need for early detection. Existing deep-learning algorithms can identify LVSD in adults using 12-lead ECG; however, their efficacy in children is uncertain. Aims: We aimed to create a deep-learning model for LVSD and RVSD detection in pediatric patients using an AI-enabled ECG and compare novel pediatric models to a previously validated adult LVSD model. Methods: We identified 10,214 pediatric patients at the Mayo Clinic with a transthoracic echocardiogram (TTE) and a 10-second, 12-lead surface ECG within 14 days of TTE, performed from 2002 -2022. Our cohort comprised the first TTE-ECG pair from each patient, totaling 138 with EF ≤ 35%, 312 with EF ≤ 50%, 482 with RVSD, and 9,567 without any LVSD or RVSD. The cohort was split into training, validation, and testing datasets to develop neural networks for systolic dysfunction detection. Results: The cohort was 52.3% male, with an average age of 10.3 years. Novel models generated in the pediatric cohort demonstrated excellent performance in systolic dysfunction detection (Figure 1). Pediatric models for EF ≤ 35% and EF ≤ 50% achieved test AUCs of 0.92 (95% CI 0.89, 0.95) and 0.89 (95% CI 0.85, 0.94) respectively. The RVSD model reached a test AUC of 0.91 (95% CI 0.88, 0.94). A combined model for EF ≤ 35% or RVSD exhibited a test AUC of 0.90 (95% CI 0.87, 0.93), sensitivity 0.88, specificity 0.82, PPV 0.20, and NPV 0.95. A combined model for EF ≤ 50% or RVSD exhibited a test AUC of 0.88 (95% CI 0.85, 0.91). The previously validated adult data-derived model achieved an AUC of 0.86 (95% CI 0.83, 0.89) for EF ≤ 50% in children. Conclusions: AI-enabled ECGs demonstrate efficient detection of both LVSD and RVSD in pediatric patients. Future multi-site validation is needed to further establish the reliability of these models.
Abstract 18797: Use of Convolutional Neural Networks to Detect Overweight and Obesity and Estimate Body Mass Index
Greason, Grace , Mangold, Kathryn, Medina-Inojosa, Betsy, Lopez‐Jimenez, Francisco, Medina‐Inojosa, Betsy J. , Naser, Jwan A. , López-Jiménez, Francisco , Attia, Zachi I.

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18797 Get It

Background: Our team has previously developed convolutional neural networks (CNNs) to estimate age and sex from a 10-second, 12-lead ECG as indicators of patient wellness. Here, we develop an additional wellness network to estimate body mass index (BMI) from the ECG input signal. Aims: To evaluate the performance of neural networks trained to classify and directly estimate BMI. Methods: We identified all adult patients in the Mayo Clinic system who had a 10-second, 12-lead ECG within 15 days of a BMI measurement. Of the&nbsp;174,863 patients in the cohort, 2,895 were underweight (BMI < 18.5), 42,387 were of normal weight (BMI 18.5-24.9), and 57,939 were overweight only (BMI 25.0-29.9). Among patients categorized as obese, 39,788 had class I obesity (BMI 30.0-34.9), 18,978 had class II obesity (BMI 35.0-39.9), and 12,876 had class III obesity (BMI ≥ 40.0). The cohort was split into training, validation, and testing datasets in an 8:1:1 ratio to develop networks for BMI classification and a direct&nbsp;estimation of BMI. Results: In detecting overweight in the testing set, the model achieved an AUC of 0.86 (95% CI 0.85, 0.87). In detecting class I, class II, and class III obesity, the model yielded AUCs of 0.84 (95% CI 0.83, 0.85), 0.84 (95% CI 0.83, 0.85), and 0.85 (95% CI 0.85, 0.86), respectively. The model to estimate BMI achieved a mean absolute error of 3.70. Conclusions: AI-enabled ECGs demonstrate efficient detection of overweight patients and all classes of obesity. Further research is needed to determine if discrepancies between the traditionally measured BMI and the AI-ECG BMI reflect the presence or lack of metabolic abnormalities.
Abstract 18718: A Deep Learning Model for Classifying Left Ventricular Enlargement Using Transthoracic and Point-of-Care Echocardiograms
Jackson, John I. , Rostami, Behrouz , Bird, Jared, Friedman, Paul A. , Kane, Garvan C. , Malins, Jeffrey G. , Anisuzzaman, DM , Lee, Eunjung , Naser, Jwan A. , López-Jiménez, Francisco , Attia, Zachi I. , Pislaru, Sorin V.

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18718 Get It

Background: Enlargement or dilation of the left ventricle (LV) is associated with increased cardiovascular morbidity and mortality, and is an established precursor of ventricular dysfunction and heart failure in almost all major cardiovascular conditions. Although there are existing artificial intelligence frameworks that make use of deep learning to detect LV enlargement, many entail LV segmentation, which can be error-prone especially for point-of-care ultrasound (POCUS) images. Goal: To develop a fully end-to-end deep learning framework that takes as input either transthoracic echocardiographic (TTE) or POCUS 2D image clips, and classifies directly (i.e., without first segmenting the LV) whether a patient has an enlarged LV. Methods: Using a sample of retrospective TTE data enriched for LV enlargement (out of 13,868 patients total, 3,351 had an enlarged LV defined using sex-specific guideline-directed criteria), we trained a classifier that takes as input apical 2-chamber and parasternal long axis videos, and provides as output a binary label denoting whether a patient has an enlarged LV. Then, we evaluated the trained model using a holdout testing dataset of retrospective TTE data (2,087 patients) as well as data from a prospective cohort of 428 patients from whom TTE and POCUS were collected simultaneously. Results: For the retrospective TTE testing dataset, the AUC was 0.851 (95% confidence interval (CI) of 0.830-871). For the prospective cohort, the model performed comparably for both TTE and POCUS video clips (TTE: AUC of 0.865, 95% CI of 0.823-0.906; POCUS: AUC of 0.840, 95% CI of 0.797-0.883). Conclusions: The current deep learning model performed comparably well for both TTE and POCUS echocardiograms. We regard these results as a proof-of-concept of the potential utility of this model in helping point-of-care clinicians make decisions regarding whether patients should receive further evaluation for LV enlargement and associated conditions.
Abstract 18713: The Impact of ECG-AI Design Choices on Clinical Utility: A Deep Dive Into Left Ventricular Hypertrophy, Hypertrophic Cardiomyopathy, and Cardiac Amyloidosis
Asfahan, Shahir , Anto, Ausath, Verma, Shiva, Friedman, Paul A. , Barve, Rakesh , Siontis, Konstantinos C. , Anto, Ausath G., Gupta, Yash, Noseworthy, Peter A. , Attia, Zachi I. , López-Jiménez, Francisco , Awasthi, Samir

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18713 Get It

Introduction: Artificial intelligence applied to electrocardiograms (ECG-AI) enables early and efficient detection of cardiovascular disease. The technical and clinical impact of different approaches to designing ECG-AI remains under-explored. We consider left ventricular hypertrophy (LVH) and examine the impact of disease-specific labeling of minority etiologies of left ventricular wall thickening- hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA) - on ECG-AI performance. Hypothesis: ECG-AI designed to detect HCM or CA outperforms ECG-AI broadly trained to identify LVH due to differences in attention to key ECG features associated with HCM or CA. Methods: Independent neural networks were trained to identify HCM, CA, and LVH. HCM and CA patients were identified using the full depth of EHR data and validated via clinician adjudication (N = 3,025 and 4,251 patients, respectively). Moderate and severe LVH patients (N = 98,144) were identified using echocardiogram results and international LVH criteria. We compared the ability of disease-specific ECG-AI vs. LVH ECG-AI to detect HCM (or CA) by examining model performance within each of the three test sets. Results: 52.6% of HCM patients and 49.5% of CA patients met LVH criteria. Within the HCM test set, the AUROC, sensitivity, specificity, and positive predictive value (PPV) of the HCM ECG-AI were 0.94, 0.88, 0.85, and 60%, respectively, whereas the same for LVH ECG-AI were 0.83, 0.83, 0.64, and 37%. Within the CA test set, CA ECG-AI achieved AUROC, sensitivity, specificity, and PPV of 0.94, 0.81, 0.91, and 69%, respectively, whereas the same for LVH ECG-AI were 0.75, 0.73, 0.68, and 31%. ECGs positive for HCM exhibited higher P wave area, QRS deflection and R wave amplitude compared to LVH-positive ECGs (Cohen's D > 0.75). ECGs positive for CA exhibited lower R wave amplitude/area, QRS deflection and QRS areas (Cohen's D > 0.6). Conclusion: Models trained using carefully labeled HCM or CA identify distinct signals associated with the diseases, resulting in improved disease discrimination compared to a model trained to identify echocardiographic left ventricular thickening. Labeling choices should be communicated transparently to clinicians to ensure safe and effective use of ECG-AI.
Abstract 18637: Lower α-Klotho is Associated With Vulnerable Coronary Artery Plaque Characteristics
Lerman, Lilach O. , Akhiyat, Nadia , Ӧzcan, Ilke , Lerman, Amir

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18637 Get It

Introduction: α-Klotho (klotho) is a geroprotective protein inversely associated with coronary artery disease CAD and vascular aging. This study used intravascular ultrasound (IVUS) to study coronary artery plaque characteristics of patients with low circulating klotho. Hypothesis: Lower klotho is associated with vulnerable coronary artery plaque characteristics. Methods: Patients undergoing coronary angiogram for chest pain who had no CAD (<40% stenosis) underwent IVUS assessment. Images were obtained from the mid-LAD to the coronary ostium. Stored arterial plasma was used for α-klotho analysis by enzyme-linked immunosorbent assay. Results: A total of 58 consecutive patients were retrospectively studied. The median circulating klotho level of the cohort was 0.27 ng/mL [0.15; 1.24]. Patients with klotho less than the median were compared to those with levels greater than or equal to the median and were similar in age (53 ±11 vs. 56 ±10, p = 0.235) and sex distribution (86% vs. 76% female, p = 0.324). Patients with less klotho had higher coronary plaque burden (21.42% [17.185, 31.955] vs. 18.32 [10.5, 24.515], p=0.041) and larger plaque area (2.71 [2.03, 4.605] vs . 2.27 [1.41, 3.31] mm 3 /mm, p=0.058) compared to those with higher klotho. Lower klotho was associated with vulnerable plaque characteristics, including greater percentages of dense calcium (1.33% [0.265, 5.38] vs. 0.43% [0.015, 1.73], p=0.037) and necrotic core (5.43% [2.245, 10.5] vs. 2.22% [0.86, 4.50], p=0.011). Conclusions: Lower circulating klotho was associated with higher coronary plaque burden and vulnerable plaque characteristics. Klotho may be an early biomarker for risk in coronary artery disease.
Abstract 18629: Discriminative Accuracy of Cha 2 Ds 2 Vasc Score, and Development of Predictive Accuracy Model Using Machine Learning for Ischemic Stroke in Cardiac Amyloidosis
Ullah, Waqas , Nair, Abhinav , Warner, Eric, Rajapreyar, Indranee, Alvarez, René , Yaddanapudi, Sridhara , Maurer, Mathew S. , Brailovsky, Yevgeniy , Brailovsky, Yevgeniy , Zahid, Salman , Frisch, Daniel R. , Rajapreyar, Indranee N. , Alkhouli, Mohamad , Maurer, Mathew S

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18629 Get It

Background: Cardiac amyloidosis (CA) in conjunction with atrial fibrillation (AF) presents unique management challenges. CHA2DS2VASc score in these patients is believed to underestimate the risk of ischemic stroke, necessitating a better predictive model in these patients. Methods: Data was obtained from the National Readmission Database (NRD). Outcomes between CA-AF and no-CA-AF were compared using multivariate regression analysis to calculate adjusted odds ratios (aOR). AutoScore; an interpretable machine learning framework, was used to develop a stroke risk prediction model, the predictive accuracy of which was evaluated with an area under the curve (AUC) using the receiver operating characteristic analysis. Results: A total of 11,860,804 (CA-AF 22,687 [0.19%] and no-CA-AF 11,838,117) patients were identified from 2015-2019. The adjusted odds of mortality (aOR 1.41 and 1.29), stroke (aOR 1.78 and 1.74), non-intracranial hemorrhage (aOR 2.10 and aOR 1.85), and intracranial hemorrhage (aOR 14.4 and aOR 4.26) were significantly higher in CA-AF compared with non-CA-AF at both index admission and 30-days, respectively. The CHA 2 DS 2 VASc score had a poor discriminative accuracy for stroke at 30-days in CA-AF (AUC 49%, 95%CI 47%-51%, p=0.54). The machine learning autoscore integrative model revealed that the predictive ability of our newly proposed E-CHADS score (end-stage renal disease (ESRD), congestive heart failure, hypertension, active cancer, dementia, and diabetes mellitus) for 30-day risk of ischemic stroke in CA-AF was excellent (for a cutoff of 52 points random forest score) with an AUC of 80% (95%CI 74%-86%) Conclusion: Cardiac amyloidosis carries a high risk of ischemic stroke that is not accurately predicted by the CHA 2 DS 2 VASc score. Our proposed model (E-CHADS) identifies 3 new variables (ESRD, dementia, and cancer) that have higher discriminative accuracy for ischemic stroke in these patients.
Abstract 18555: Global Burden of Congenital Heart Disease and Its Trend From 1990-2019 in 38 OECD Countries: A Benchmarking Analysis for the Global Burden of Disease Study
Patel, Hardik Y, Ratheesh, Rani, anum, anum, Thota, Anjani Kumar, Rachapudi, Shasank, John, Jobby , Koppana, Viswaja, Hassan, Khawaja Muthammir , Anum, ., Desai, Hardik Dineshbhai

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18555 Get It

Introduction: Congenital heart disease (CHD) is the 1st leading cause of deaths among all deaths associated with congenital birth defects in (Organization for Economic Cooperation and Development) OECD countries, constituting a significant health concern that imposes a substantial burden on healthcare systems and society. Methods: Using the Global Burden of Disease methodology, this study assesses the prevalence, incidence, mortality, and disability-adjusted life years (DALYs) associated with CHD in 38 OECD countries by sex, year, and location, covering the period from 1990 to 2019. The results are presented in both all age counts and age standardized rates (ASR) per 100,000 person-years. Results: From 1990 to 2019, the total number of prevalent cases of CHD increased from 1,469,128 (95%UI: 1,292,909-1,671,743) to 1,590,654 (1,387,114-1,815,338). In contrast, CHD-related deaths decreased from 37,291 (31,629-47,869) in 1990 to 13,886 (10,668-16,919) in 2019. The annual percentage of change (APC) in age-standardized mortality (ASMR) decreased by 60%, while the ASIR showed almost no change but decreased by 3%. Notably, the highest APC in ASIR was observed in Czechia (27%), Sweden (21%), Hungary (18%), and the United States (11%), while Turkey (28%) and Canada (21%) had the lowest APC increases. The highest APC increase in ASIR among females was observed in France (29%) Conclusions: Despite a decrease in the burden of CHD over the last three decades, it remains a significant concern in OECD countries. The impact of CHD is felt by individuals, families, healthcare systems, and the economy, emphasizing the ongoing need for comprehensive strategies to address this burden.
Abstract 18546: Vasoactive Medication Variability in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
Banna, Soumya, Chouairi, Fouad , Heck, Cory, Grammatico, Megan, Kochar, Ajar , Miao, Jennifer , Ali, Tariq , Miller, Elliott, Schenck, Christopher S. , Jentzer, Jacob C. , Diepen, Sean van

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18546 Get It

Background: Patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS) often require vasoactive medications to maintain organ perfusion. However, there are limited data on the real-world use of vasoactive medications in this population. Methods: We used the Vizient® Clinical Data Base to identify patients aged ≥18 years who were admitted between 2015-2019 with AMI-CS and required mechanical ventilation. We report the proportion of patients receiving vasoactive medications by day as well as site-level variability for vasoactive medication strategies using the median odds ratio (MOR), which quantifies the odds that a patient receives a strategy at two randomly selected sites after adjusting for covariates. Results: We identified 10,758 patients from 160 centers admitted with AMI-CS. The median age was 65.8 years, 29.8% were female, 83.6% received vasoactive medications in the first 5 days, and 56.9% received temporary mechanical support. The most used vasoactive medication on day 1 was norepinephrine (48.2%), followed by epinephrine (31.5%), and dopamine (16.9%) ( Figure ). On day 1, 65.9% and 36.2% of patients receiving vasoactive medications were prescribed ≥2 or ≥3 different medications, respectively, including 111 different combinations. Among patients receiving inotropes (N=4,485), there was a nearly 3-fold difference in milrinone use across sites after accounting for differences in patient characteristics (MOR 2.89; 95% confidence interval [CI]: 2.39-3.38). For patients receiving either norepinephrine, dopamine, or epinephrine on day 1 (N=3,224), there was a nearly 2-fold difference in the use of norepinephrine as a first-line vasopressor across sites (MOR 1.84; 95% CI: 1.59-2.06). Conclusion: Norepinephrine is the most commonly used vasoactive medication in patients with AMI-CS. However, there is substantial site-level variability in vasoactive medication strategies, which require further study.
Abstract 18463: Direct Oral Anticoagulants versus Vitamin K Antagonists in Morbidly Obese Patients (BMI ≥ 40): An Updated Systematic Review and Meta-Analysis
Malik, Saad Ullah , Qadeer, Abdul , Shafique, Nouman, Mustafa, Bisher, Akbar, Usman Ali

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18463 Get It

Introduction: The safety and efficacy of direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKAs) remain unknown in patients with BMI ≥ 40 kg/m 2 . We aim to evaluate the risk of recurrent VTE and major bleeding in patients with a BMI ≥ 40 when started on DOACs versus VKAs. Methods: We conducted a systematic literature search according to PRISMA guidelines to identify studies using the terms: “venous thromboembolism”, “Vitamin K antagonists” and “direct oral anticoagulants”. After the screening, We extracted the data till May 2023 in a data extraction sheet. Our inclusion criteria were: adult patients, morbidly obese (BMI ≥ 40 kg/m 2 ), who were on DOACs or VKAs for VTE or atrial fibrillation. We used a variance-weighted random-effects model to analyze data on DOACs vs. VKAs, estimating event rates and odds ratios while assessing heterogeneity. Data were analyzed using the ‘meta’ package in R. Results: Our analysis included a total of 16 studies (n= 62704 patients). Obese patients on DOACs had a significant reduction in the risk of recurrent VTEs compared to VKAs OR 0.72 (95% CI: 0.59 - 0.88, I2 :19%). Also, DOACs were associated with a lower risk of major bleeding compared to VKAs in morbidly obese patients (OR = 0.65, 95% CI: 0.58 - 0.74, I2 :0%). For non-major bleeding, although the statistical significance was not reached, a consistent trend favoring DOACs was observed (OR = 0.76, 95% CI: 0.47-1.21). (Figure1) Conclusions: Among morbidly obese patients (BMI ≥ 40), DOACs are associated with a significantly lower risk of recurrent VTEs, and major bleeding compared to VKA. For non-major bleeding, there was a trend favoring DOACs over VKA. Increased recruitment of obese patients in clinical trials is needed to provide us with robust data for informed clinical decision-making.